IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management describes a multi-year initiative to restore balance by investing in R&D, strengthening capabilities, and rebuilding the go-to-market approach, with an explicit assessment that the R&D pipeline was “not what it should have been” about 2.5 years ago, but has since improved materially. 12 Specifically, IFF says it now has a “very strong R&D capability,” “great perfumers,” an improved “pipeline of molecules as well as delivery systems,” and is addressing gaps while building an “absolutely leading-edge” pipeline for Fine Fragrances and Consumer Fragrances. 2
Why this drives recovery: a stronger molecule/delivery-system pipeline supports new product creation and improves competitiveness—laying groundwork for market-share gains that management directly ties to the Scent recovery narrative. 12
In Q2, Fine Fragrance finished “up slightly positive” versus expectations of “down…mid-single digits,” and management attributes this to “a very good job at managing the challenges in the Middle East.” 3 Management also frames the recovery path as: softer near-term due to uncertainty and comps, then “recovery as we get to Q4.” 3
Why this drives recovery: stabilizing performance through a volatile geopolitical period helps prevent further demand erosion and preserves momentum for later-quarter normalization. 3
For Consumer Fragrance, management highlights rebuilding “the R&D capability [and] go-to-market approach with customers” and “trying to drive market share gains.” 4 They also report that the R&D team has strengthened and that leadership/teams are committed to leadership in Scent. 2
Why this drives recovery: Consumer Fragrance performance is framed as dependent on both innovation (R&D) and commercial execution with customers, which can reaccelerate growth once channel and customer programs align. 42
Although the question is about Scent recovery broadly, IFF’s reported Scent segment performance in Q2 is described as driven by Fragrance Ingredients growth “north of 20%,” with part of the outperformance due to the prior-year comparison (“comparing to a down 10% or more in the year ago period”). 3
They also state the team “strategically leveraged the synthetics portfolio to capture more sales” amid macro/supply chain disruptions and higher Brent crude prices, but expect normalization so that growth shifts back toward “higher value-added ingredients versus…traditional synthetics.” 3
Why this matters to Scent recovery: strong Fragrance Ingredients performance helps lift consolidated Scent sales, but management is explicit that it is not expected to remain as strong indefinitely—meaning future Scent recovery relies more on the innovation/market-share work in Fine and Consumer Fragrance and on the shift to higher-value natural products. 43
Net interpretation: Fine Fragrance recovery is staged—Q3 likely faces tougher comps/volatility, while Q4 improves as those dynamics ease. 43
Net interpretation: Consumer Fragrance is expected to cool from a strong Q2, but remain on a positive growth path (low single-digit), supported by improved R&D capability and customer-facing execution. 4
In addition to Fine and Consumer Fragrance, IFF expects Fragrance Ingredients to normalize going forward and be slightly under pressure year-over-year as a result of that shift; however, they emphasize the team’s progress on compounds and the move toward “higher-value natural products” that will strengthen competitiveness over time (not necessarily in the second half, but “as we go into next year and the year after”). 4
Implication for 2H: Even if Fine/Consumer Fragrance recover as guided, the overall Scent growth profile in 2H is moderated by expected ingredients normalization, making the Fine/Q4 improvement and Consumer/low-single-digit stability especially important to Scent recovery. 43
Management states it is “very pleased” with progress over the last ~2.5 years and that the R&D pipeline and perfumers are now producing “leading-edge new Fine Fragrances and Consumer Fragrances,” with a strong pipeline of “molecules as well as delivery systems.” 2
They also explicitly say that while the higher-value natural products shift in Fragrance Ingredients is “underway” and will take time, by next year and the year after they expect “a really strong competitive position.” 4 Since 2027 falls into that “next year and the year after” horizon, this is the closest direct statement tying R&D/innovation direction to 2027 competitiveness. 4
Management’s recovery plan is described as including not only investment in R&D, but also rebuilding the “go-to-market approach with customers” to drive market-share gains in Consumer Fragrance. 4 The same leadership message emphasizes addressing R&D gaps and strengthening strengths. 2
Implication for 2027: R&D support is not framed as “internal science only,” but as a pipeline plus commercialization loop—innovation that is matched to customer programs and share recovery efforts. 42
Management highlights that the R&D pipeline was previously behind expectations, but now is “very strong,” and they have built “great perfumers” and a “great pipeline” spanning molecules and delivery systems. 2 This suggests the 2027 plan is to leverage a now-rebuilt R&D engine rather than wait for an entirely new rebuild. 2
While not a Scent-only statement, management frames the broader Remainco strategy as requiring continued reinvestment in R&D/innovation, explicitly describing R&D spend as being in an “8% to 9% range” and emphasizing “innovation matters” as the “circle” where investments improve growth and allow margin reinvestment. 5
Why it matters: it supports the idea that R&D funding and prioritization are expected to persist through the 2027 horizon as part of the transformation strategy. 5
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi